How is Boey different from Botox?

Boey has a faster onset and shorter duration compared to Botox, offering more flexibility.

When will Boey be available in Europe?

AbbVie has not yet announced a commercial launch date.

What is AbbVie's stock ticker?

AbbVie trades on the NYSE under the ticker ABBV.

AbbVie Wins EU Approval for New Frown Line Treatment Boey

AbbVie (ABBV) announced EU approval for Boey (trenibotulinumtoxinE) via its Allergan Aesthetics unit. Boey is the first rapid-onset, short-duration neurotoxin for frown lines in Europe, expanding AbbVie's aesthetics portfolio.

July 17, 2026

1 min read

Source: Simply Wall St.

AbbVie (NYSE:ABBV) announced that its Allergan Aesthetics unit has received European Commission approval for Boey (trenibotulinumtoxinE) to treat frown lines. Boey is described as the first rapid onset, short duration neurotoxin available in Europe for this indication.

The Product

Boey offers a faster onset and shorter duration of effect compared to existing treatments, providing patients with more flexibility. It specifically targets glabellar lines (frown lines), a common area for aesthetic procedures.

Pricing and Availability

Pricing and launch timeline have not been disclosed yet.

Competition

Boey will compete with established products like Botox (also from AbbVie), Dysport, and Xeomin. Its unique profile may appeal to patients seeking quick results and shorter recovery.

Potential Impact on AbbVie

The approval strengthens AbbVie's aesthetics portfolio in Europe, where it already has a strong presence. Boey could help capture new market share among patients desiring more customizable treatment options.

Frequently Asked Questions

Boey (trenibotulinumtoxinE) is a rapid onset, short duration neurotoxin for frown lines, approved in Europe.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.